Medtronic is linking its implanted devices with Samsung’s phones and tablets to better monitor the effectiveness of neuromodulation technologies. (Click to view Samsung release.)
Those with implanted neurostimulators, which send electronic signals to targeted areas of the brain to block symptoms, can have a more active role in the management of their diseases. Parkinson’s, essential tremor and dystonia patients will hopefully benefit from the initiative.
Data from the devices will be sent to a patient’s mobile devices, including phones, wearables and tablets, in real time. It can also be sent directly to a doctor to help them better understand patient symptoms and progress, and appropriately adjust therapies.
The two companies announces a similar partnership for the management of diabetes earlier this year.
Wearable Tech + Digital Health San Francisco – April 5, 2016 @ the Mission Bay Conference Center
NeuroTech San Francisco – April 6, 2016 @ the Misson Bay Conference Center
Wearable Tech + Digital Health NYC – June 7, 2016 @ the New York Academy of Sciences
NeuroTech NYC – June 8, 2016 @ the New York Academy of Sciences
MIT’s Oliver Jonas, Robert Langer, and colleagues have developed an implantable device that allows doctors to test cancer drugs in patients before prescribing chemotherapy.
The tiny device can carry small doses of 30 drugs. After implanting it in a tumor and allowing the drugs to diffuse into the tissue, researchers can measure how effectively each destroys a patient’s cancer cells. The guesswork involved in choosing treatments can be minimized.
Most cancer drugs work by damaging DNA or interfering with cell function. Scientists have developed more targeted drugs, designed to kill tumor cells that carry a specific genetic mutation. However, it is usually difficult to predict whether a particular drug will be effective in an individual patient.
Doctors sometimes extract tumor cells, grow them in a lab, and treat them with different drugs to determine which are most effective. This process removes the cells from their natural environment, which can play an important role in a tumor’s response to drug treatment.
According to Jonas, the implant “essentially puts the lab into the patient. It’s safe, and sensitivity testing can be done in the native microenvironment.”
WEARABLE TECH + DIGITAL HEALTH NYC 2015 – JUNE 30 @ NEW YORK ACADEMY OF SCIENCES. REGISTER HERE.